1. European Medicines Agency
. Biosimilar medicines: overview [Internet], 2017. Available from https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview. Accessed 24 October 2019
2. Medicines, Diagnostics and Personalised Medicine Policy Team, National Medical Directorate, NHS England
. Commissioning framework for biological medicines (including biosimilar medicines)[Internet], 2017. Available from https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicines-commissioning-framework.pdf. Accessed 24 October 2019
3. Generics and Biosimilars Initiative (GaBI)
. Biosimilars of insulin glargine [Internet], 2018. Available from http://gabionline.net/Biosimilars/General/Biosimilars-of-insulin-glargine. Accessed 24 October 2019
4. European Medicines Agency
. Lantus: European Public Assessment Report (EPAR) for the public [Internet]. Available from https://www.ema.europa.eu/en/documents/product-information/lantus-epar-product-information_en.pdf. Accessed 31 October 2019
5. Association of British Clinical Diabetologists (ABCD) position statement on the use of biosimilar insulin;Jayagopal;Br J Diabetes,2018